BQ-123

DB12054InvestigationalSmall molecule

BQ-123 has been investigated for the basic science and treatment of Coronary Artery Disease, Aorto-coronary Bypass Grafting, and ST-Elevation Myocardial Infarction.

Mechanism: Pharmacologically active on Endothelin-1 receptor
Curator reviewed
Formula / weight: C₃₁H₄₂N₆O₇ · 610.712 g/mol (avg)
Code names: BQ-123

Resolves to

Compound

UNIIS2A8YZM151CAS136553-81-6ChEMBLCHEMBL314691ChEBI2965PubChem443289KEGGC11587

Structure

InChIKeyVYCMAAOURFJIHD-PJNXIOHISA-NSMILESCC(C)C[C@@H]1NC(=O)[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@@H](CC(O)=O)NC(=O)[C@@H](CC2=CNC3=CC=CC=C23)NC1=O)C(C)C

Targets

P25101EDNRA

What you can answer from here — as of August 30, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

633Drug interactionsStructured to mechanism, not free text

19Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with BQ-123, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account